Inactive Instrument

Highlights Amarantus BioSciences Inc OTC Bulletin Board

Equities

US02300Q1058

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2022	Sector Update: Financial Stocks Still Adding to Wednesday Declines	MT
2020	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	20-07-27	CI
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	20-01-29	CI
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	20-01-02	CI
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	19-11-21	CI
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	19-10-24	CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	19-10-23	CI
Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation	19-06-25	CI
Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome	19-06-18	CI
Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc..	19-04-21	CI
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries	19-01-11	CI
Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop Alzheimer’S Blood Diagnostic Lympro Test 2.0	18-12-03	CI
Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	18-11-27	CI
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test Vs. Amyloid Pet	18-05-04	CI
Amarantus BioScience Holdings, Inc. (‘AMBS’) acquired certain assets of Avant Diagnostics, Inc. (‘Avant’) for $0.05 million.	18-04-05	CI
Amarantus BioScience Holdings, Inc. Announces Executive Changes	18-04-05	CI
Amarantus Bioscience Holdings, Inc & MANF Therapeutics, Inc. Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF	17-12-14	CI
Amarantus Bioscience Holdings, Inc cancelled the acquisition of biomedical assets from SeD BioMedical Inc.	17-09-29	CI
Amarantus Bioscience Holdings, Inc. Establishes Two New Subsidiaries	17-04-17	CI
Amarantus Bioscience Seeks Acquisitions	17-02-27	CI
Amarantus Bioscience Holdings, Inc signed a letter of intent to acquire biomedical assets from SeD BioMedical Inc.	17-02-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amarantus BioSciences Inc OTC Bulletin Board

Equities

US02300Q1058

Highlights

Filters